Business
TOPROL XL TOPROL XL (metoprolol succinate extended-release) is a cardioselective beta-blocker indicated for the treatment of hypertension, which has been on the U.S. market since 1992.
CorMedix Inc.: Revenue grew 617% to $312M from $43.47M. Net income turned positive at $163M from a $17.93M loss. Free cash flow turned positive at $173M from a $50.73M outflow. Operating margin expanded 9960 bps to 48.17%. CorMedix Inc.'s annual comparison also shows capital spending grew faster than revenue; the manipulation screen is flagged and should be investigated as a warning rather than treated as proof.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 617% to $312M from $43.47MOK
- Profitability — Net income turned positive at $163M from a $17.93M lossOK
- Cash flow — Free cash flow turned positive at $173M from a $50.73M outflowOK
- Margins — Operating margin expanded 9960 bps to 48.17%OK
- Accounting — Controls ineffective; weakness under remediationWatch
- Insiders — 1 purchase and 13 salesOK
Where the revenue comes from
Fiscal 2025, as CorMedix Inc. reports it. History and quarterly detail are in the app.
- Product$304.3M
- Defen Cath$258.8M
- Melinta Portfolio$45.5M
- Contract Revenue$7.4M
Leadership changes
From CorMedix Inc.'s own filings, the day they're filed.
- Paulo F. Costa · member · departureeff. 2023-10-15
- Susan Blum · Chief Financial Officer · appointment
- Elizabeth Hurlburt · Chief Financial Officer · appointment
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-07
- 8-K · Company announcement2026-07-02
- 8-K · Company announcement2026-07-01
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CorMedix Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.